

# Alaska Medical Assistance DUR Committee Meeting Minutes

---

Friday, January 15, 2021

Meeting was held Telephonically due to COVID-19. 1:00PM

## Drug Utilization Review Committee Attendees

Members Present	Non Members Present
Erin Narus, PharmD (DHSS)	Umang Patel, PharmD (Magellan)
Charles Semling, PharmD (DHSS)	Ryan Ruggles, PharmD, MSHI (Magellan)
Charles Ryan, MD	
Robert Carlson, MD	
Barb Piromalli, DO	
Keri McCutcheon, RPh	Members Absent
	Dr. Heath McAnally, MD
	Jonathon Harrison, PharmD

### Call to order at 1:02 PM.

### Review of Agenda

Charles Semling went over the Agenda to the committee members.

### Review of minutes from November 2020

Charles Semling asked the committee if they had any changes to the minutes. There were none.

Motion to approve Keri McCutcheon.

Second by Barb Piromalli.

Minutes approved.

Keri McCutcheon, RPh commented on the benefits of the 90 day insulins.

### Overview of Medicaid Prescription and Cost Trends

Charles Semling went through the detail of the program trend snapshot. Claims increased and high dollar medications made up a large portion of that trend. Charles Semling specifically mentioned antiarthritics.

Both PMPM/PUPM trends are up for the last month, likely due to the COVID early fills.

The top 25 by therapeutic class drives the majority of the increases. Top 25 drugs increasing drug spend, one drug are increasing the drug spend. One drug specifically is driving some trend. Rare disease and biologics are largely driving the spend.

## Prospective Drug Utilization Review/Clinical Topic Areas

### New Prescription Medications (Interim PA List – 6 month review)

Interim PA list was short for this meeting. Charles Semling presented the logic for these medications and conditions that they treat. The committee agreed that the list seemed reasonable.

### New Prior Authorizations, Quantity Limits, Edits

Ofev criteria was presented.

It was reviewed by the committee.

Dr. Carlson mentioned that it looks reasonable.

Keri McCutcheon moved to approve.

Second by Barb Piromalli

Fintepla criteria was presented.

It was reviewed by the committee.

Erin Narus requested the requirement of the diagnosis on the submitted claim.

After brief discussion to address to the reasoning and benefits for the request, Keri McCutcheon moved to approve with changes.

Barb Piromalli seconded.

Kesimpta criteria was presented.

It was reviewed by the committee.

Success and failure was mentioned to be added, and it was pointed out with MS it may be difficult to predict a success and failure.

Added a criteria to ensure adequate trial for the same specific indication.

Keri McCutcheon moved to approve with changes.

Charles Ryan seconded.

Xcopri criteria was presented.

It was reviewed by the committee.

Charles Ryan moved to approve as written.

Keri McCutcheon seconded.

Lovaza and Vascepa criteria was presented.

It was reviewed by the committee.

Barb Piromalli moved to approve.

Charles Ryan seconded.

Eucrisa criteria was presented.

It was reviewed by the committee.  
Charels Ryan moved to approve with appropriate “AND” and “OR”.  
Keri McCutcheon seconded.

The committee asked about trends for lidocaine patch use. They requested several reports including: 5% ointment change from patch. Reject Claims. Previous/concomitant Opioid use. Committee discussion lead to discuss using an ICD10 for approval, and removing the current PA. Charles Ryan moves to approve with monitoring. Keri McCutcheon seconded.

## Opioid Report

Charles Semling presented the opioid use tables.  
There was some brief discussion about drugs moving in certain directions, and a comment regarding, MME can be a little deceiving if you don't know the indication, hospice/cancer, etc.  
He mentioned the idea of letters to send to prescribers for concomitant use of BZD and Opioids.  
He also mentioned the positive response he had received from the provider community regarding the Z drug and benzodiazepine combination.  
Keri McCutcheon moved to approve the letter.  
Robert Carlson seconded.

## Safety Reports

Charles Semling presented the FDA safety report regarding NSAID use

## FAERS Reports

There were no FAERS reports to review.

## Specialty Drug Class on the Alaska PDL

The idea of creating a specialty drug list in order to help control cost was presented to the committee. The state assured the committee it would not adversely effect pharmacies as most of these drugs have limited distribution or other programs that drive to the specialty pharmacies.

## Post meeting comments

Robert Carlson commented on the benefits of using the Zoom platform over previous versions of telecommuting for this committee.

## End of Public Meeting

## Adjournment 3:01 p.m.

Next meeting date April 16<sup>th</sup>, 2021.